Erdafitinib, a small molecule inhibitor of fibroblast growth factor receptor (FGFR), is active in platinum refractory BlCa expressing FGFR3 mutations and FGFR2/3 fusions [195]. The gene discussed is FGFR3; the disease is bladder transitional cell carcinoma.